FDA Approves Arrowhead's First Drug for Rare Genetic Fat Disorder
FDA approves Arrowhead Pharmaceuticals' Redemplo for familial chylomicronemia syndrome, a rare genetic disorder causing dangerously high blood fat levels.
/ 913 items
#Healthcare↓
LifeMD Shares Tumble on Earnings Miss and GLP-1 Market Struggles
LifeMD stock plunged 25% after missing Q3 earnings and cutting guidance, citing fierce competition from low-cost compounded GLP-1 weight loss drugs despite Novo and Lilly partnerships.
Roche's Giredestrant Success: Cutting Breast Cancer Recurrence Risk
Roche’s experimental SERD, giredestrant, showed unprecedented success in a late-stage trial, cutting recurrence risk in early-stage, ER-positive breast cancer.
Merck’s WINREVAIR Met Primary Endpoint in Combined Pulmonary Hypertension
Merck’s WINREVAIR met its goal in a Phase 2 study for CpcPH, a tough heart/lung disease. It helps blood move through the lungs better.
Citi Surprised by Hims Exclusion as Novo Cuts GLP-1 Prices
Citi analyst Daniel Grosslight says competition is increasing in weight-loss drug pricing after Novo Nordisk introduced a $199 monthly offer for Wegovy and Ozempic, leaving out Hims & Hers as a distribution partner.
CRISPR Therapeutics Stock Rises on Takeover Rumors
CRISPR Therapeutics shares climbed after rumors suggested a large U.S. biopharma company may be exploring a potential acquisition, fueled by progress in gene editing programs and growing Casgevy sales.